NCT02644616View on ClinicalTrials.gov

The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Tricuspid RegurgitationRight Heart Failure
Interventions
DRUG

tolvaptan+torasemide

tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv

DRUG

placebo+torasemide

placebo 15mg/d po(10 days) +torasemide 20mg/d iv

Trial Locations (1)

Unknown

FangYuan, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER

NCT02644616 - The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement | Biotech Hunter | Biotech Hunter